Drug Type Small molecule drug |
Synonyms Pozanicline, Pozanicline Tartrate, A-87089 + [2] |
Mechanism nAChR α4/β2/α5 agonists(Nicotinic acetylcholine receptor alpha4/beta2/alpha5 agonists), α3β4 receptor antagonists(Neuronal acetylcholine receptor; alpha3/beta4 antagonists), α7 receptor agonists(Neuronal acetylcholine receptor protein alpha-7 subunit agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC11H18Cl2N2O |
InChIKeyUGVSESCRKJTJAK-XRIOVQLTSA-N |
CAS Registry161416-61-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Pozanicline Hydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Phase 2 | US | 01 Oct 2006 | |
Alzheimer Disease | Phase 2 | US | 01 Jul 2003 |
Phase 2 | 17 | (ABT-089) | wxryksmyrm(clasgmufwq) = zaixoocjwh mqiylztalh (uupatyfauo, njtvvadsso - udjdjepvjx) View more | - | 29 Oct 2014 | ||
Placebo (Placebo) | wxryksmyrm(clasgmufwq) = qtoauhoiey mqiylztalh (uupatyfauo, oqubwfofcw - oaxaoqotlk) View more |